What do you think will be the next "big innovation" regarding AGA? 6/20/2024
The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Peptides that Stop Hair Loss? | In-depth Literature Review Video
Peptides like TB500, KPV, GHK-CU, and BPC-157 are overhyped for hair growth with limited proven effectiveness in humans. Combining peptides with delivery methods like iontophoresis and sonophoresis shows promise, but many claims remain unproven.
community I interviewed Kintor: GT20029 Clinical Trial Pictures. As well as KX826.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
community We live in the weirdest time to suffer Androgenetic Alopecia and this weird subreddit will probably be of some historic interest in the future.
Hair loss treatments like finasteride, minoxidil, and RU58841 are becoming more known, but many remain unaware of their effectiveness. There is hope for future advancements despite skepticism and misconceptions about current treatments.
community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
Related Research
6 / 6 results
research Use of Verteporfin with Dermal Wounding to Regenerate New Hair in Androgenetic Alopecia
In this study, two male patients with androgenetic alopecia who had previously undergone hair transplants showed increased hair regrowth after receiving verteporfin injections, with a 63% mean increase in dense donor sites, 38% in thinning areas, but no growth in bald areas.
research Applications and Risks of Nanomaterials Used in Regenerative Medicine, Delivery Systems, Theranostics, and Therapy
This review classifies engineered nanomaterials by composition and application in biomedicine, highlighting diverse uses like regenerative medicine and potential occupational side effects, but reports no new clinical results.
research Farmácia Central de Almada - Almada e nos Serviços Farmacêuticos do Hospital Garcia de Orta - Almada
Pharmacists play a crucial role in customizing treatments and ensuring medication safety.
research Advances in Research of Hydrogel Microneedle-Based Delivery Systems for Disease Treatment
This review examines hydrogel microneedles for transdermal drug delivery, discussing their applications and challenges but reports no new clinical results.
research Microneedle-Mediated Transdermal Drug Delivery for the Treatment of Multiple Skin Diseases
This study highlights the clinical potential of microneedles as an innovative transdermal drug delivery system for treating various skin diseases with minimal pain and high patient compliance.
research Recent Advances in the Structural Design of Photosensitive Agent Formulations Using “Soft” Colloidal Nanocarriers
This review discusses the advancements in using "soft" colloidal nanocarriers for delivering photosensitive agents and highlights their potential applications in treating diseases like cancer, but it reports no new clinical results.